PSP94 Immunoassay for Urine Specimens (ELISA)

Catalog Number PSP94U0001

For research use only: not for use in diagnostic procedures

The Miraculins PSP94 kit is an enzyme linked immunosorbent assay (ELISA) research use only (RUO) product not intended for use in diagnostic procedures, for the detection of PSP94 in urine. The PSP94 ELISA kit utilizes a peroxidase enzyme that produces a color that is compatible with microtiter plate readers. The kit includes a precoated 96 well plate of anti-PSP94, an anti-PSP94 peroxidase conjugate, a PSP94 calibrator, wash buffer, assay buffer, color developer and a stop solution. The Miraculins’ PSP94 ELISA kit is highly sensitive which allows the customer to minimize the effect of potential interfering substances by diluting urine samples in assay buffer. The coefficient of variation (CV) for the assay is less than 7% and the dilution linearity of urine is nearly perfect correlation coefficient of 0.999.

Prostate Secretory Protein (PSP94), also known as beta-microseminoprotein, or inhibin-like peptide, is a basic 94 amino acid protein with a Mw of 10,704. PSP94 is generated from a 114 amino acid precursor whose DNA sequence is located on chromosome 102. Purified PSP94 isolated from seminal fluid migrates between 13 – 16 KDa on a polyacrylamide gel. The difference in MW is not due to glycosylation but due the basic nature of the protein. Despite a growing body of evidence linking PSP94 to the development and prognosis of prostate cancer it has not been approved for diagnostic use as a tool to assist in making informed clinical decisions ^(1-3).

PSP94 is found in high concentration in the epithelial cells of the prostate⁽⁴⁾. A 31 amino acid cleavage product of PSP94 found in seminal fluid demonstrates the ability to inhibit FSH release⁽⁵⁾. PSP94 has been examined in serum and urine for its potential utility as a biomarker. Results demonstrated that PSP94 was not detectable in PC-3 cell line from human prostatic carcinomas⁽⁶⁾. Furthermore, PSP94 in urine has been shown to be decreased in men with late stage tumors using 24 hr collection^(7-9). Miraculins has completed a number of studies which have added to the body of evidence that PSP94 is decreased in the urine of men with prostate cancer. Miraculins studies have also suggested potential utility when combined with other biomarkers such as total PSA or Free/Total PSA. Further research is needed to confirm the clinical utility of PSP94 alone or in combination with other biomarkers.

Technical Resources

• Information for Use Supplement
• Material Data Safety Sheet

Kit Contains

Part #	Label	Material Description	Amount
N/A	N/A	Mylar Plate Sealers	4 piece
MoM000135	25x Wash Concentrate	25X Wash Buffer with ProClin 300 (20 mL)	1 vial
MoM0000145	5x Assay Buffer	5X Assay Buffer with ProClin 300 (23 mL)	1 vial
MoM0000475	PSP94 ELISA Plate	Precoated Plates - PSP94 (1 x 96 well plate)	1 plate *
MoM0000545	Anti-PSP94 Conjugate Concentrate	PSP94 Conjugate Concentrate in stabilizers with ProClin 300 (200 µL)	1 vial
MoM0000555	TMB Solution	TMB Solution (10 mL)	1 vial
MoM0000435	0.2N Stop Solution	0.2N sulfuric acid stop solution (5 mL)	1 vial
MoM0000425	PSP94 12ng/mL Calibrator	12 ng/mL PSP94 Calibrator stock solution in stabilizers with ProClin (1 mL)	1 vial

* Please contact us at sales@miraculins.com for partial plates in 4x24 well or 2x 48 well or to order individual kit components

References

1. Whitaker HC, Warren AY, Eeles R, Kote-Jarai Z, Neal DE. The potential value of microseminoprotein-beta as a prostate cancer biomarker and therapeutic target. Prostate 2010; 70:333-40.
2. Seidah NG, Arbatti NJ, Rochemont J, Sheth AR, Chretien M. Complete amino acid sequence of human seminal plasma beta-inhibin. Prediction of post Gln-Arg cleavage as a maturation site. FEBS Lett 1984; 175:349-55.
3. Dube JY, Frenette G, Paquin R, et al. Isolation from human seminal plasma of an abundant 16-kDa protein originating from the prostate, its identification with a 94-residue peptide originally described as beta-inhibin. J Androl 1987; 8:182-9.
4. Brar A, Mbikay M, Sirois F, Fournier S, Seidah NG, Chretien M. Localization of the human prostatic secretory protein PSP94 and its mRNA in the epithelial cells of the prostate. J Androl 1988; 9:253-60.
5. Ramasharma K, Sairam MR, Seidah NG, et al. Isolation, structure, and synthesis of a human seminal plasma peptide with inhibin-like activity. Science 1984; 223:1199-202.
6. Kaighn ME, Narayan KS, Ohnuki Y, Lechner JF, Jones LW. Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol 1979; 17:16-23.
7. Teni TR, Sheth AR, Kamath MR, Sheth NA. Serum and urinary prostatic inhibin-like peptide in benign prostatic hyperplasia and carcinoma of prostate. Cancer Lett 1988; 43:9-14.
8. Teni TR, Bandivdekar AH, Sheth AR, Sheth NA. Prostatic inhibin-like peptide quantified in urine of prostatic cancer patients by enzyme-linked immunosorbent assay. Clin Chem 1989; 35:1376-9.
9. Tremblay J, Frenette G, Tremblay RR, Dupont A, Thabet M, Dube JY. Excretion of three major prostatic secretory proteins in the urine of normal men and patients with benign prostatic hypertrophy or prostate cancer. Prostate 1987; 10:235-43.

Pricing